Hypocalcemia has been found to be significantly associated with PD-1 inhibitor pembrolizumab treatment in a recent meta-analysis by Manohar et al. [5], notably as rare (11 out of 604 patients) grade 1–3 adverse events, but the pathomechanism is usually unknown. The gene discussed is PDCD1; the disease is Hypocalcemia.